^○Michina OKADA¹, Takamichi KOGURE^{1, 3, 4, 5}, Takanori KOMURO¹, Hideyuki NISHIDA¹, Shutaro SUGITA^{1, 2}, Takuya NAKASONE¹, Tomoyuki TACHIBANA^{1, 2}, Isao KASUGA¹, Yuji NISHI¹, Naoki HANAOKA¹, Makiko SUGAWA⁵, Masahiko SUMITANI⁴, Kazuo KAWAHARA⁵, Toru DAMBARA¹, Tadashi MURAKAMI¹ (1. Sanmaibashi Hospital, 2. Department of Psychiatry, School of Medicine, Showa University, 3. Department of Anesthesiology and Pain Relief Center, The University of Tokyo Hospital, 4. Department of Palliative Medicine, The University of Tokyo Hospital, 5. Department of Health Policy Science Tokyo Medical and Dental University Graduate School of Medical and Dental Science)

^○Itaru MIURA¹, Tadashi NOSAKA², Hirooki YABE¹, Katsuhiko HAGI² (1. Department of Neuropsychiatry, Fukushima Medical University School of Medicine, Fukushima, Japan, 2. Medical Affairs, Sumitomo Dainippon Pharma Co., Ltd.)

^○Tomoyo YANAGIDA, Naotaka SUNADA, Yuichi KITAURA, yositeru TAKEKITA, Tosihiko KINOSITA, Masaki KATO (Department of Neuropsychiatry, Kansai Medical University)

^○Jun ISHIGOOKA¹, Ken INADA², Kazuo AOKI³, Kazunari NIIDOME³, Shuichi IWASHITA³, Tomohiro USAMI³ (1. Institute of CNS Pharmacology, Japan, 2. Tokyo Women's Medical University, 3. Otsuka Pharmaceutical Co., Ltd.)